Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

5 S,15 S-Dihydroperoxyeicosatetraenoic Acid (5,15-diHpETE) as a Lipoxin Intermediate: Reactivity and Kinetics with Human Leukocyte 5-Lipoxygenase, Platelet 12-Lipoxygenase, and Reticulocyte 15-Lipoxygenase-1.

Green AR, Freedman C, Tena J, Tourdot BE, Liu B, Holinstat M, Holman TR.

Biochemistry. 2018 Nov 15. doi: 10.1021/acs.biochem.8b00889. [Epub ahead of print]

PMID:
30407793
2.

The Protease-Activated Receptor 4 Ala120Thr Variant Alters Platelet Responsiveness to Low-Dose Thrombin, Protease-Activated Receptor 4 Desensitization and Is Blocked by Noncompetitive P2Y12 Inhibition.

Whitley MJ, Henke DM, Ghazi A, Nieman M, Stoller M, Simon LM, Chen E, Vesci J, Holinstat M, McKenzie SE, Shaw CA, Edelstein LC, Bray PF.

J Thromb Haemost. 2018 Oct 22. doi: 10.1111/jth.14318. [Epub ahead of print]

PMID:
30347494
3.

Characterization of hemostasis in mice lacking the novel thrombosis susceptibility gene Slc44a2.

Tilburg J, Adili R, Nair TS, Hawley ME, Tuk DC, Jackson M, Spronk HM, Versteeg HH, Carey TE, van Vlijmen BJM, Maracle CX, Holinstat M.

Thromb Res. 2018 Nov;171:155-159. doi: 10.1016/j.thromres.2018.09.057. Epub 2018 Sep 26.

PMID:
30312801
4.

Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids.

Adili R, Hawley M, Holinstat M.

Prostaglandins Other Lipid Mediat. 2018 Nov;139:10-18. doi: 10.1016/j.prostaglandins.2018.09.005. Epub 2018 Sep 25. Review.

PMID:
30266534
5.

Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases.

Yeung J, Li W, Holinstat M.

Pharmacol Rev. 2018 Jul;70(3):526-548. doi: 10.1124/pr.117.014530. Review.

PMID:
29925522
6.

TC21/RRas2 regulates glycoprotein VI-FcRγ-mediated platelet activation and thrombus stability.

Janapati S, Wurtzel J, Dangelmaier C, Manne BK, Bhavanasi D, Kostyak JC, Kim S, Holinstat M, Kunapuli SP, Goldfinger LE.

J Thromb Haemost. 2018 Jun 8. doi: 10.1111/jth.14197. [Epub ahead of print]

PMID:
29883056
7.

Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics.

Tourdot BE, Stoveken H, Trumbo D, Yeung J, Kanthi Y, Edelstein LC, Bray PF, Tall GG, Holinstat M.

Arterioscler Thromb Vasc Biol. 2018 Jul;38(7):1632-1643. doi: 10.1161/ATVBAHA.118.311112. Epub 2018 May 10.

8.

New LINE(s) of Evidence for Genetic Regulation of Platelets.

Holinstat M.

Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):690-691. doi: 10.1161/ATVBAHA.118.310690. No abstract available.

PMID:
29563112
9.

Modified two-step emulsion solvent evaporation technique for fabricating biodegradable rod-shaped particles in the submicron size range.

Safari H, Adili R, Holinstat M, Eniola-Adefeso O.

J Colloid Interface Sci. 2018 May 15;518:174-183. doi: 10.1016/j.jcis.2018.02.030. Epub 2018 Feb 9.

PMID:
29454188
10.

12-HETrE inhibits platelet reactivity and thrombosis in part through the prostacyclin receptor.

Tourdot BE, Adili R, Isingizwe ZR, Ebrahem M, Freedman JC, Holman TR, Holinstat M.

Blood Adv. 2017 Jun 23;1(15):1124-1131. doi: 10.1182/bloodadvances.2017006155. eCollection 2017 Jun 27.

11.

In vivo modeling of docosahexaenoic acid and eicosapentaenoic acid-mediated inhibition of both platelet function and accumulation in arterial thrombi.

Adili R, Voigt EM, Bormann JL, Foss KN, Hurley LJ, Meyer ES, Veldman AJ, Mast KA, West JL, Whiteheart SW, Holinstat M, Larson MK.

Platelets. 2017 Dec 29:1-9. doi: 10.1080/09537104.2017.1420154. [Epub ahead of print]

PMID:
29286871
12.

Neutrophil-Particle Interactions in Blood Circulation Drive Particle Clearance and Alter Neutrophil Responses in Acute Inflammation.

Fromen CA, Kelley WJ, Fish MB, Adili R, Noble J, Hoenerhoff MJ, Holinstat M, Eniola-Adefeso O.

ACS Nano. 2017 Nov 28;11(11):10797-10807. doi: 10.1021/acsnano.7b03190. Epub 2017 Oct 19.

PMID:
29028303
13.

Targeting 12-Lipoxygenase as a Potential Novel Antiplatelet Therapy.

Tourdot BE, Holinstat M.

Trends Pharmacol Sci. 2017 Nov;38(11):1006-1015. doi: 10.1016/j.tips.2017.08.001. Epub 2017 Aug 29. Review.

PMID:
28863985
14.

First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis.

Adili R, Tourdot BE, Mast K, Yeung J, Freedman JC, Green A, Luci DK, Jadhav A, Simeonov A, Maloney DJ, Holman TR, Holinstat M.

Arterioscler Thromb Vasc Biol. 2017 Oct;37(10):1828-1839. doi: 10.1161/ATVBAHA.117.309868. Epub 2017 Aug 3.

15.

Anti-inflammatory ω-3 endocannabinoid epoxides.

McDougle DR, Watson JE, Abdeen AA, Adili R, Caputo MP, Krapf JE, Johnson RW, Kilian KA, Holinstat M, Das A.

Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6034-E6043. doi: 10.1073/pnas.1610325114. Epub 2017 Jul 7.

16.

Normal platelet function.

Holinstat M.

Cancer Metastasis Rev. 2017 Jun;36(2):195-198. doi: 10.1007/s10555-017-9677-x. Review.

17.

The expansive role of oxylipins on platelet biology.

Yeung J, Hawley M, Holinstat M.

J Mol Med (Berl). 2017 Jun;95(6):575-588. doi: 10.1007/s00109-017-1542-4. Epub 2017 May 20. Review.

18.

Who is the real 12-HETrE?

Yeung J, Holinstat M.

Prostaglandins Other Lipid Mediat. 2017 Sep;132:25-30. doi: 10.1016/j.prostaglandins.2017.02.005. Epub 2017 Mar 1. Review.

19.

Complement factors (H) into thrombosis.

Holinstat M.

Blood. 2017 Mar 2;129(9):1065-1066. doi: 10.1182/blood-2017-01-761528. No abstract available.

20.

Identification of a functional genetic variant driving racially dimorphic platelet gene expression of the thrombin receptor regulator, PCTP.

Kong X, Simon LM, Holinstat M, Shaw CA, Bray PF, Edelstein LC.

Thromb Haemost. 2017 May 3;117(5):962-970. doi: 10.1160/TH16-09-0692. Epub 2017 Mar 2.

21.

Exploring deformable particles in vascular-targeted drug delivery: Softer is only sometimes better.

Fish MB, Fromen CA, Lopez-Cazares G, Golinski AW, Scott TF, Adili R, Holinstat M, Eniola-Adefeso O.

Biomaterials. 2017 Apr;124:169-179. doi: 10.1016/j.biomaterials.2017.02.002. Epub 2017 Feb 4.

22.

Evaluation of Receptor-Ligand Mechanisms of Dual-Targeted Particles to an Inflamed Endothelium.

Fromen CA, Fish MB, Zimmerman A, Adili R, Holinstat M, Eniola-Adefeso O.

Bioeng Transl Med. 2016 Mar;1(1):103-115. doi: 10.1002/btm2.10008. Epub 2016 Apr 27.

23.

Development of Poly Unsaturated Fatty Acid Derivatives of Aspirin for Inhibition of Platelet Function.

Roy J, Adili R, Kulmacz R, Holinstat M, Das A.

J Pharmacol Exp Ther. 2016 Oct;359(1):134-41. doi: 10.1124/jpet.116.234781. Epub 2016 Aug 3.

24.

12(S)-HETrE, a 12-Lipoxygenase Oxylipin of Dihomo-γ-Linolenic Acid, Inhibits Thrombosis via Gαs Signaling in Platelets.

Yeung J, Tourdot BE, Adili R, Green AR, Freedman CJ, Fernandez-Perez P, Yu J, Holman TR, Holinstat M.

Arterioscler Thromb Vasc Biol. 2016 Oct;36(10):2068-77. doi: 10.1161/ATVBAHA.116.308050. Epub 2016 Jul 28.

25.

Protease receptor antagonism to target blood platelet therapies.

Holinstat M, Bray PF.

Clin Pharmacol Ther. 2016 Jan;99(1):72-81. doi: 10.1002/cpt.282. Epub 2015 Nov 18. Review.

PMID:
26501993
26.

Dual antiplatelet therapy for PCI: Are we tailored to all?

Holinstat M, Reheman A.

Thromb Res. 2015 Jun;135(6):1045-6. doi: 10.1016/j.thromres.2015.04.008. Epub 2015 Apr 12. No abstract available.

PMID:
25900309
27.

Coronary heart disease risk factors take a disproportional toll on women.

Holinstat M, Tourdot BE.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):750-1. doi: 10.1161/ATVBAHA.115.305466. No abstract available.

28.

Discovery of ML355, a Potent and Selective Inhibitor of Human 12-Lipoxygenase.

Luci D, Jameson JB II, Yasgar A, Diaz G, Joshi N, Kantz A, Markham K, Perry S, Kuhn N, Yeung J, Schultz L, Holinstat M, Nadler J, Taylor-Fishwick DA, Jadhav A, Simeonov A, Holman TR, Maloney DJ.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2013 Apr 12 [updated 2014 Sep 18].

29.

Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race.

Edelstein LC, Simon LM, Lindsay CR, Kong X, Teruel-Montoya R, Tourdot BE, Chen ES, Ma L, Coughlin S, Nieman M, Holinstat M, Shaw CA, Bray PF.

Blood. 2014 Nov 27;124(23):3450-8. doi: 10.1182/blood-2014-04-572479. Epub 2014 Oct 7.

30.

Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis.

Tourdot BE, Conaway S, Niisuke K, Edelstein LC, Bray PF, Holinstat M.

Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2644-50. doi: 10.1161/ATVBAHA.114.304249. Epub 2014 Oct 2.

31.

Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation.

Yeung J, Tourdot BE, Fernandez-Perez P, Vesci J, Ren J, Smyrniotis CJ, Luci DK, Jadhav A, Simeonov A, Maloney DJ, Holman TR, McKenzie SE, Holinstat M.

Blood. 2014 Oct 2;124(14):2271-9. doi: 10.1182/blood-2014-05-575878. Epub 2014 Aug 6.

32.

Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects.

Cleator JH, Duvernay MT, Holinstat M, Colowick NE, Hudson WJ, Song Y, Harrell FE, Hamm HE.

J Pharmacol Exp Ther. 2014 Oct;351(1):33-43. doi: 10.1124/jpet.114.215616. Epub 2014 Jul 22.

33.

MicroRNA expression differences in human hematopoietic cell lineages enable regulated transgene expression.

Teruel-Montoya R, Kong X, Abraham S, Ma L, Kunapuli SP, Holinstat M, Shaw CA, McKenzie SE, Edelstein LC, Bray PF.

PLoS One. 2014 Jul 16;9(7):e102259. doi: 10.1371/journal.pone.0102259. eCollection 2014.

34.

Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics.

Simon LM, Edelstein LC, Nagalla S, Woodley AB, Chen ES, Kong X, Ma L, Fortina P, Kunapuli S, Holinstat M, McKenzie SE, Dong JF, Shaw CA, Bray PF.

Blood. 2014 Apr 17;123(16):e37-45. doi: 10.1182/blood-2013-12-544692. Epub 2014 Feb 12.

35.

The emerging role of oxylipins in thrombosis and diabetes.

Tourdot BE, Ahmed I, Holinstat M.

Front Pharmacol. 2014 Jan 7;4:176. doi: 10.3389/fphar.2013.00176. eCollection 2014 Jan 7. Review.

36.

Synthesis and structure-activity relationship studies of 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase.

Luci DK, Jameson JB 2nd, Yasgar A, Diaz G, Joshi N, Kantz A, Markham K, Perry S, Kuhn N, Yeung J, Kerns EH, Schultz L, Holinstat M, Nadler JL, Taylor-Fishwick DA, Jadhav A, Simeonov A, Holman TR, Maloney DJ.

J Med Chem. 2014 Jan 23;57(2):495-506. doi: 10.1021/jm4016476. Epub 2014 Jan 6.

37.

Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c.

Edelstein LC, Simon LM, Montoya RT, Holinstat M, Chen ES, Bergeron A, Kong X, Nagalla S, Mohandas N, Cohen DE, Dong JF, Shaw C, Bray PF.

Nat Med. 2013 Dec;19(12):1609-16. doi: 10.1038/nm.3385. Epub 2013 Nov 10.

38.

MicroRNAs in platelet production and activation.

Edelstein LC, McKenzie SE, Shaw C, Holinstat MA, Kunapuli SP, Bray PF.

J Thromb Haemost. 2013 Jun;11 Suppl 1:340-50. doi: 10.1111/jth.12214. Review.

39.

12-lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivity.

Yeung J, Apopa PL, Vesci J, Stolla M, Rai G, Simeonov A, Jadhav A, Fernandez-Perez P, Maloney DJ, Boutaud O, Holman TR, Holinstat M.

Thromb Haemost. 2013 Sep;110(3):569-81. doi: 10.1160/TH13-01-0014. Epub 2013 Jun 20. Erratum in: Thromb Haemost. 2014 Aug;112(2):426.

40.

Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation.

Holinstat M, Colowick NE, Hudson WJ, Blakemore D, Chen Q, Hamm HE, Cleator JH.

J Thromb Thrombolysis. 2013 Feb;35(2):209-22. doi: 10.1007/s11239-012-0812-9.

41.

Investigations of human platelet-type 12-lipoxygenase: role of lipoxygenase products in platelet activation.

Ikei KN, Yeung J, Apopa PL, Ceja J, Vesci J, Holman TR, Holinstat M.

J Lipid Res. 2012 Dec;53(12):2546-59. doi: 10.1194/jlr.M026385. Epub 2012 Sep 13.

42.

Newer agents in antiplatelet therapy: a review.

Yeung J, Holinstat M.

J Blood Med. 2012;3:33-42. doi: 10.2147/JBM.S25421. Epub 2012 Jun 25. Erratum in: J Blood Med. 2012;3:49.

43.

Protein kinase C regulation of 12-lipoxygenase-mediated human platelet activation.

Yeung J, Apopa PL, Vesci J, Kenyon V, Rai G, Jadhav A, Simeonov A, Holman TR, Maloney DJ, Boutaud O, Holinstat M.

Mol Pharmacol. 2012 Mar;81(3):420-30. doi: 10.1124/mol.111.075630. Epub 2011 Dec 9.

44.

We can do it together: PAR1/PAR2 heterodimer signaling in VSMCs.

Pawlinski R, Holinstat M.

Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2775-6. doi: 10.1161/ATVBAHA.111.238865. No abstract available.

45.

Rap1-Rac1 circuits potentiate platelet activation.

Stefanini L, Boulaftali Y, Ouellette TD, Holinstat M, Désiré L, Leblond B, Andre P, Conley PB, Bergmeier W.

Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):434-41. doi: 10.1161/ATVBAHA.111.239194. Epub 2011 Nov 10.

46.

12-lipoxygenase: a potential target for novel anti-platelet therapeutics.

Yeung J, Holinstat M.

Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):154-64. Review.

47.

Discovery of potent and selective inhibitors of human platelet-type 12- lipoxygenase.

Kenyon V, Rai G, Jadhav A, Schultz L, Armstrong M, Jameson JB 2nd, Perry S, Joshi N, Bougie JM, Leister W, Taylor-Fishwick DA, Nadler JL, Holinstat M, Simeonov A, Maloney DJ, Holman TR.

J Med Chem. 2011 Aug 11;54(15):5485-97. doi: 10.1021/jm2005089. Epub 2011 Jul 8.

48.

Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2α differently for cyclooxygenase-1 and 12-lipoxygenase catalysis.

Holinstat M, Boutaud O, Apopa PL, Vesci J, Bala M, Oates JA, Hamm HE.

Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):435-42. doi: 10.1161/ATVBAHA.110.219527. Epub 2010 Dec 2.

49.

Role of protein kinase Czeta in thrombin-induced RhoA activation and inter-endothelial gap formation of human dermal microvessel endothelial cell monolayers.

Minshall RD, Vandenbroucke EE, Holinstat M, Place AT, Tiruppathi C, Vogel SM, van Nieuw Amerongen GP, Mehta D, Malik AB.

Microvasc Res. 2010 Sep;80(2):240-9. doi: 10.1016/j.mvr.2010.04.007. Epub 2010 Apr 24.

50.

Irreversible platelet activation requires protease-activated receptor 1-mediated signaling to phosphatidylinositol phosphates.

Holinstat M, Preininger AM, Milne SB, Hudson WJ, Brown HA, Hamm HE.

Mol Pharmacol. 2009 Aug;76(2):301-13. doi: 10.1124/mol.109.056622. Epub 2009 May 29.

Supplemental Content

Loading ...
Support Center